40.255 USD
-0.45 (-1.09%)
Last: Feb 4, 2026, 10:27 AM
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make CORT a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year CORT was profitable.
- CORT had a positive operating cash flow in the past year.
- CORT had positive earnings in each of the past 5 years.
- Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 12.88%, CORT belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
- CORT's Return On Equity of 16.79% is amongst the best of the industry. CORT outperforms 89.01% of its industry peers.
- CORT's Return On Invested Capital of 8.69% is amongst the best of the industry. CORT outperforms 87.43% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CORT is significantly above the industry average of 12.83%.
- The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(8.69%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROIC | 8.69% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
- Looking at the Profit Margin, with a value of 14.32%, CORT belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
- In the last couple of years the Profit Margin of CORT has declined.
- Looking at the Operating Margin, with a value of 8.85%, CORT belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
- In the last couple of years the Operating Margin of CORT has declined.
- CORT has a Gross Margin of 98.19%. This is amongst the best in the industry. CORT outperforms 96.86% of its industry peers.
- In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
- CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- CORT has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CORT has less shares outstanding
- There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 16.15 indicates that CORT is not in any danger for bankruptcy at the moment.
- CORT has a better Altman-Z score (16.15) than 84.82% of its industry peers.
- There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.15 |
ROIC/WACC0.91
WACC9.54%
2.3 Liquidity
- A Current Ratio of 3.14 indicates that CORT has no problem at all paying its short term obligations.
- With a Current ratio value of 3.14, CORT perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
- CORT has a Quick Ratio of 3.07. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
- CORT has a Quick ratio (3.07) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 |
3. Growth
3.1 Past
- The earnings per share for CORT have decreased strongly by -30.16% in the last year.
- CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
- The Revenue has grown by 17.92% in the past year. This is quite good.
- Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
3.2 Future
- The Earnings Per Share is expected to grow by 44.06% on average over the next years. This is a very strong growth
- CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.55% yearly.
EPS Next Y-28.44%
EPS Next 2Y-36.38%
EPS Next 3Y33.27%
EPS Next 5Y44.06%
Revenue Next Year17.6%
Revenue Next 2Y23.01%
Revenue Next 3Y25%
Revenue Next 5Y23.55%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 45.74, CORT can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 76.44% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.18, CORT is valued quite expensively.
- With a Price/Forward Earnings ratio of 80.21, CORT can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than the industry average as 68.59% of the companies are valued more expensively.
- CORT is valuated expensively when we compare the Price/Forward Earnings ratio to 25.51, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.74 | ||
| Fwd PE | 80.21 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than 77.49% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 82.20% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.05 | ||
| EV/EBITDA | 53.62 |
4.3 Compensation for Growth
- The excellent profitability rating of CORT may justify a higher PE ratio.
- CORT's earnings are expected to grow with 33.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)4.71
EPS Next 2Y-36.38%
EPS Next 3Y33.27%
5. Dividend
5.1 Amount
- No dividends for CORT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CORT (2/4/2026, 10:27:50 AM)
40.255
-0.45 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-18 2026-02-18/amc
Inst Owners75.42%
Inst Owner Change-1.74%
Ins Owners6.65%
Ins Owner Change0.41%
Market Cap4.23B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts75
Price Target92.82 (130.58%)
Short Float %8.81%
Short Ratio3.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.78%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)-28.45%
PT rev (3m)-32.7%
EPS NQ rev (1m)-11.27%
EPS NQ rev (3m)-24.58%
EPS NY rev (1m)-10.31%
EPS NY rev (3m)-12.78%
Revenue NQ rev (1m)-2.22%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)-0.71%
Revenue NY rev (3m)-4.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.74 | ||
| Fwd PE | 80.21 | ||
| P/S | 5.71 | ||
| P/FCF | 26.05 | ||
| P/OCF | 26 | ||
| P/B | 6.7 | ||
| P/tB | 6.7 | ||
| EV/EBITDA | 53.62 |
EPS(TTM)0.88
EY2.19%
EPS(NY)0.5
Fwd EY1.25%
FCF(TTM)1.55
FCFY3.84%
OCF(TTM)1.55
OCFY3.85%
SpS7.05
BVpS6.01
TBVpS6.01
PEG (NY)N/A
PEG (5Y)4.71
Graham Number10.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROCE | 10.07% | ||
| ROIC | 8.69% | ||
| ROICexc | 24.92% | ||
| ROICexgc | 24.92% | ||
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% | ||
| FCFM | 21.93% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.2% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 245.43% | ||
| Profit Quality | 153.21% | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 | ||
| Altman-Z | 16.15 |
F-Score6
WACC9.54%
ROIC/WACC0.91
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-28.44%
EPS Next 2Y-36.38%
EPS Next 3Y33.27%
EPS Next 5Y44.06%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year17.6%
Revenue Next 2Y23.01%
Revenue Next 3Y25%
Revenue Next 5Y23.55%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-24.4%
EBIT Next 3Y37.86%
EBIT Next 5Y19.15%
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CORT.
Can you provide the valuation status for CORCEPT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.
Can you provide the profitability details for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CORCEPT THERAPEUTICS INC (CORT) stock?
The Price/Earnings (PE) ratio for CORCEPT THERAPEUTICS INC (CORT) is 45.74 and the Price/Book (PB) ratio is 6.7.